The Supreme Court will pronounce on Monday its verdict in a landmark patent case involving Swiss pharma giant Novartis AG.

The company has challenged the denial of patent to its blood cancer drug Glivec in India The verdict, which is crucial even for public health, is being watched closely by global pharmaceutical firms, who have been pushing for stronger patent protection in India to regulate the country's $26-billion generic drug industry.